Ask Stago (english version) – Details, episodes & analysis

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

In today’s episode, Karine Carrière  will explain further what are microvesicles, their importance in coagulation and how to analyze them. 

Literature sources:

• [Tesselaar et al.], [Lacroix et al.] [Faille et al.] [Mullier et al.] Vallier et al.] . [Nieuwland et al.]
• Kim HK, Song KS, Park YS, Kang YH, Lw YJ, Lw KR, et al.
• Elevated levels of circulating platelet microparticles, VEGF, 11-6 and
• FiANTES in patients Wlth gastrlc cancer. possible mle of a metastasis
• predlotor. Eur J Cancer 2003;39(2):184-91.
• Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fiher AM, et al. Platelet microparticles: a potential predictive factor of survival in hormone-reac pmstate cancer patients treated with docetaxel-based chemotherapy. Eur Urnl2009;56(3):479-84.
• Zwicker JI, Liebman HA, Neuberg D, Lecmix R, Bauer KA, Furie BC, et ai. Tmr-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15 (22): 68630-40

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.

This month we meet Joseph Bautista, is a 37 year old US man living with a rare clotting disorder, a Factor XI deficiency otherwise known as Hemophilia C. His journey so far has not been an easy one but by educating himself and advocating for the best care he is living a full and healthy life working as a data architect in the IT sector. Its an inspiring and reassuring story for anyone facing a rare bleeding disorder diagnosis & proves the importance of patient empowerment.

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.

In today episode, our expert Lydie Nicoud, R&D reagent manager, will talk with us about the test of fibrinogen. 

As usual, don’t forget to send any question you may have to ask@stago.com, we will be glad to answer to it.

Literature sources:

• Miesbach W, Schenk J, Alesci S, Lindhoff-Last E, Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia .Thromb Res. 2010; 126(6): e428-33
• Karapetian H. Reptilase time (RT). Methods Mol Bio 2013; 992:273-7.
• Mackie IJ, Kitchen S, Machin SJ, Lowe GDO, Guidelines on fibrinogen assays, Br J Hematol 2003; 121: 396-404
• Cunningham MT, Olson JD, Chandler WL, Van Cott EM, Eby CS, Teruya J, Hollensead SC, Adcock DM, Allison PM, Kottke-Marchant KK, Smith MD. External quality assurance of fibrinogen assays using normal plasma: results of the 2008 College of American Pathologists proficiency testing program in coagulation. Arch Pathol Lab Med. 2012 Jul;136(7):789-95. doi: 10.5858/arpa.2011-0322-OA. PMID: 22742551.Siriez R, Dogné JM, Gosselin R, Laloy J, Mullier F, Douxfils J Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory. Int J Lab Hematol 2021; 43(1): 7-20

Related podcasts:

• S1E9: How to manage HIL samples in the coagulation laboratory?

  https://www.podcastics.com/podcast/episode/9-how-to-manage-hil-samples-in-the-coagulation-laboratory-37748/

   
• S1E15: Disseminated Intravascular Coagulation (DIC) and fibrin related markers.

  https://www.podcastics.com/podcast/episode/15-disseminated-intravascular-coagulation-dic-and-fibrin-related-markers-54016/

   
• S2E6: Prothrombin Time routine does not mean "simple". 

  https://www.podcastics.com/podcast/episode/s2e6-prothrombin-time-routine-does-not-mean-simple-69494/

• S2E7: APTT, not a one-for-all purposes reagent.

  https://www.podcastics.com/podcast/episode/s2e7-aptt-not-a-one-for-all-purposes-reagent-70596/

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

In today’s episode, our guest Dr Bryan G Fry, aka Venom Doc, will make us enter his world and understand how venom interact with coagulation and how they can prove useful for assay or drug design & development

Literature sources:

• Fry BG, Roelants K, Champagne DE, Scheib H, Tyndall JD, King GF, Nevalainen TJ, Norman JA, Lewis RJ, Norton RS, Renjifo C, de la Vega RC. The toxinogenomic multiverse: convergent recruitment of proteins into animal venoms. Annu Rev Genomics Hum Genet. 2009, 10: 483-511.
• Bittenbinder, M. A., C. N. Zdenek, B. Op den Brouw, N. J. Youngman, J. S. Dobson, A. Naude, F. J. Vonk and B. G. Fry (2018). "Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib)." Toxins (Basel) 10(12): 516.
• Chowdhury, A., M. R. Lewin, C. N. Zdenek, R. Carter and B. G. Fry (2021a). "The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms." Front Immunol 12: 752442.
• Seneci, L., C. N. Zdenek, A. Chowdhury, C. F. B. Rodrigues, E. Neri-Castro, M. Benard-Valle, A. Alagon and B. G. Fry (2021). "A Clot Twist: Extreme Variation in Coagulotoxicity Mechanisms in Mexican Neotropical Rattlesnake Venoms." Front Immunol 12: 612846.
• Chowdhury, A., C. N. Zdenek, J. S. Dobson, L. A. Bourke, R. Soria and B. G. Fry (2021b). "Clinical implications of differential procoagulant toxicity of the palearctic viperid genus Macrovipera, and the relative neutralization efficacy of antivenoms and enzyme inhibitors." Toxicol Lett 340: 77-88.
• Chowdhury, A., C. N. Zdenek, M. R. Lewin, R. Carter, T. Jagar, E. Ostanek, H. Harjen, M. Aldridge, R. Soria, G. Haw and B. G. Fry (2021). "Venom-Induced Blood Disturbances by Palearctic Viperid Snakes, and Their Relative Neutralization by Antivenoms and Enzyme-Inhibitors." Frontiers in Immunology 12: 2251.
• Zdenek, C. N., B. O. den Brouw, D. Dashevsky, A. Gloria, N. Youngman, E. Watson, P. Green, C. Hay, N. Dunstan, L. Allen and B. G. Fry (2019a). "Clinical implications of convergent procoagulant toxicity and differential antivenom efficacy in Australian elapid snake venoms." Toxicol Lett 316: 171-182.
• Zdenek, C. N., C. Hay, K. Arbuckle, T. N. W. Jackson, M. H. A. Bos, B. Op den Brouw, J. Debono, L. Allen, N. Dunstan, T. Morley, M. Herrera, J. M. Gutierrez, D. J. Williams and B. G. Fry (2019b). "Coagulotoxic effects by brown snake (Pseudonaja) and taipan (Oxyuranus) venoms, and the efficacy of a new antivenom." Toxicol In Vitro 58: 97-109.
• Sousa, L. F., C. A. Nicolau, P. S. Peixoto, J. L. Bernardoni, S. S. Oliveira, J. A. Portes-Junior, R. H. Mourao, I. Lima-dos-Santos, I. S. Sano-Martins, H. M. Chalkidis, R. H. Valente and A. M. Moura-da-Silva (2013). "Comparison of phylogeny, venom composition and neutralization by antivenom in diverse species of bothrops complex." PLoS Negl Trop Dis 7(9): e2442.
• Rogalski, A., C. Soerensen, B. Op den Brouw, C. Lister, D. Dashevsky, K. Arbuckle, A. Gloria, C. N. Zdenek, N. R. Casewell, J. M. Gutierrez, W. Wuster, S. A. Ali, P. Masci, P. Rowley, N. Frank and B. G. Fry (2017). "Differential procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of antivenom efficacies." Toxicol Lett 280: 159-170.
• Youngman, N. J., J. Llinas and B. G. Fry (2021). "Evidence for Resistance to Coagulotoxic Effects of Australian Elapid Snake Venoms by Sympatric Prey (Blue Tongue Skinks) but Not by Predators (Monitor Lizards)." Toxins (Basel) 13(9).

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.

In today’s episode, our guest François Depasse will help us to understand the hemostasis results obtained along pregnancy, what are the related difficulties for the lab and

Link to previous podcasts:

• S1E15 Disseminated Intravascular Coagulation (DIC) and fibrin related markers:

  https://www.podcastics.com/podcast/episode/15-disseminated-intravascular-coagulation-dic-and-fibrin-related-markers-54016/

• S2E1 Whole Blood Viscoelastic Testing (VET)

  https://www.podcastics.com/podcast/episode/s2e1-whole-blood-viscoelastic-testing-vet-55204

Literature sources:

• Szecsi PB, Jørgensen M, Klajnbard A, Andresen MR, Colov NP, Stender S, Haemostatic reference intervals in pregnancy. Thromb Haemost 2010; 2013: 718-27
• Kristoffersen AH, Peters PH, Bjørge L, Røraas T and Sandberg S. Concentration of fibrin monomer in pregnancy and during the postpartum period. Annals of Clinical Biochemistry 2019; 56(6): 692-700.
• Hellgren H. Hemostasis during normal prgenancy and puerperium. Semin Thromb Hemost. 2003; 29(2): 125-30.
• Leduc L, Wheeler JM, Kirshon B, Mitchell P, Cotton DB, Coagulation profile in severe preeclampsia, Obstet Gynecol 1992 79(1); 14-8
• Gillissen A, van den Akker T, Caram-Deelder C, Henriquez DDCA, Bloemenkamp KWM, de Maat MPM, van Roosmalen JJM, Zwart JJ, Eikenboom J, van der Bom JG. Coagulation parameter during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. Blood Adv 2018; 2(19): 2433-42
• Ducloy-Bouthors AS, Mercier FJ, Grouin JM, Bayoumey F, Corouge I, Le Goueze A, Rackelboom T, Broisin F, Vial F, Luzi A, Capronnier O, Huissoud C, Mignon A, Early and systematic administration of fibrinogen concentrate in post-partum haemorrhage following vaginal delivery: the FIDEL randomized controlled trial. BJOG 2021. 128:1814-23.
• Brenner A, Ker K, Shakur-Still H, Roberts I. Tranexamic acid for post-partum haemorrhage: what, who and when. Best Pract Res Clin Obstet Gynaecol. 2019; 1:66-74

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

In today’s episode, our guest Sophie Réhault will give us explanations on what is the new EU IVD regulation and what it implies both for IVD manufacturers and for the clinical laboratories. 

Link to previous podcasts: 

• S2E18 – Practical check list of the implementation of an instrument in your lab:

  https://www.podcastics.com/podcast/episode/s2e18-practical-check-list-of-the-implementation-of-an-instrument-in-your-lab-103649/

   
• S3E4 – All you need to know about instrument validation: 

  https://www.podcastics.com/podcast/episode/s3e4-all-you-need-to-know-about-instrument-vlalidation-120105/

Literature sources:

• Regulation (EU) 2017/746 (IVDR) of the Europan Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and commission Decision 2010/227/EU
• European Parliament Legislative resolution of 15 December 2021 on te proposal for a regulation of the European Parliament and of the Council amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and deferred application of requirements for in house devices (COM(2021) 0627-C9-0381/2021 – 2021/0323 (COD))
•  

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

In today’s episode, our guest Daniel Pilbeam, from the Clinical Pathology Laboratory at UVet in Melbourne will help us understand the common points and differences between veterinary and human hemostasis, and what should be critically assessed.

Previous episodes in relation to the topic:

•  AskStago episode #9 (season 1): How to manage HIL samples in the coagulation laboratory?

Literature sources:

• John W. Harvey, Veterinary Hematology, Chapter 7 - Evaluation of Hemostasis: Coagulation and Platelet Disorders, W.B. Saunders, 2012, Pages 191-233, ISBN 9781437701739, https://doi.org/10.1016/B978-1-4377-0173-9.00007-5.
• Beurlet S, Coisnon C, Nguyen TT, Richet M, Carlo A, Briend-Marchal A. Comparison of STA-NeoPTimal (Stago) and STA-Neoplastine CI Plus (Stago) thromboplastin reagents using a STA Satellite Max analyzer to measure prothrombin times in dogs. Vet Clin Pathol. 2021 Sep;50(3):348-353. doi: 10.1111/vcp.12949.
• A previous pathologist, Bruce Parry, also co-wrote a paper that was instrumental in identifying cut offs for factor deficiencies that we still use the reference range for today.

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in coagulation.

In today’s episode, our guest Kaitlyn Pelc will explain further the different steps to validate an instrument at the installation.

Previous episodes in relation to the topic:

• S2E18 – Practical check list of the implementation of an instrument in your lab: https://www.podcastics.com/podcast/episode/s2e18-practical-check-list-of-the-implementation-of-an-instrument-in-your-lab-103649/
• S2E3 – How to establish and control the reference range of my assay: https://www.podcastics.com/podcast/episode/s2e3-how-to-establish-and-control-the-reference-range-of-my-assay-60155/
• S2E2 - How to calibrate your reagent as a pro: https://www.podcastics.com/podcast/episode/s2e2-how-to-calibrate-your-reagent-as-a-pro-58249/

Literature sources:

• CLSI. Protocol for the Evaluation, Validation and Implementation of Coagulometers; Approved Guideline. CLSI document H57-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
• CLSI. One-Stage Prothrombin Time (PT-Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline- Second Edition. CLSI document H47-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
• CLSI. Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline. CLSI document H54-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
• CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline- Third Edition. CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
• CLSI. Measurement Procedure Comparison and Bias Estimation Using Patient Samples. 3rd ed. CLSI guideline EP09c. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
• CLSI. User Verification of Precision and Estimation of Bias; Approved Guideline- Third Edition. CLSI document EP15-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
• College of American Pathologists.  All Common Checklist. Northfield, IL: College of American Pathologists; 2021.

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.

In today’s episode, our guest David Courtois will explain further what is platelet aggregometry, how to measure it and in which indications it is useful.

Literature sources:

• Born GVR. Aggregation of blood platelets by adenosine disphosphate and its reversal. Nature 1962; 194: 927 – 929.
• O’Brien JR. Platelet aggregation. II. Some results from a new method of study. J Clin Pathol 1962; 15: 452-458.
• Caen JP, Michel H. Platelet shape change and aggregation. Nature 1972; 240 (5377): 148-149.
• Holmsen H. Platelet metabolism and activation Semin Hematol. 1985; 22 (3): 2 19-40.
• Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation in Methods in Hematology, Churchill Livingstone, New-York 1983; 8: 64-91.
• Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005; 123 (2): 172-183.
• Hvas AM, Favaloro EJ. Platelet function analyzed by light transmission aggregometry. Methods Mol Biol 2017; 1646: 321-331.
• Christie DJ, Avari T, Carrington LR, Cohen E, DeBiase BA, Harrison P, Kickler TS, Kottke-Marchant K, Ledford-Kraemer M, Rand ML, Schmaier AH, McCabe White M. Platelet function testing by aggregometry: approved guidelines, H58-A. Clinical and Laboratory Standards Institute: Wayne, PA, USA 2008; 28 (31): 1-45.
• Frontroth, J.P.; Favaloro, E.J. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies. Methods Mol. Biol. 2017, 1646, 473–494.
• Hayward CPM, Pai M, Liu Y, Moffat KA, Seecharan J, Weber KE, Cook RJ, Heddle NM. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorders assessments. J Throm Haemost 2009; 7 (4): 676-684
• Cattaneo M., Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSCC of the ISTH. J. Thromb Haemost 2009; 7: 1029
• Hayward CPM, Moffat KA, Raby A, Israels S, Plumhoff E, Flynn G, Zehnder J.L. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134: 955-963.
• Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S. British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155: 30-44
• Dawood BB, Lowe GC, Lordkipanidze M, Bem D, Daly ME, Makris M, Mumford A, Wilde JT, Watson SP. Evaluation of participants with suspected heritable platelet function disorder including recommendation and validation of a streamlined agonist panel. Blood 2012; 120 (25): 5041-5049.
• Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, Nurden P, Rao KA, Schmaier AH, Watson SP, Lussana F, Pugliano MT. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Throm Haemost 2013; 11: 1183-1189.
• Rao AK. Inherited platelet function disorders: overview and disorders of granules, secretion, and signal transduction. Hematol Oncol Clin North Am 2013; 27 (3): 585-611.
• Nurden AT, Nurden P. Inherited disorders of platelet function: selected updates. J Thromb Haemost 2015; 13 (Suppl 1): 2-9.
• Frelinger AL 3rd, Gachet C, Mumford AD, Noris P, Mezzano D, Harrison P, Gresele P. Laboratory monitoring P2Y12 inhibitors communication from the SSC of the ISTH. J Throm Haemost 2018; 16 (11): 2341-2346
• Podda G, Scavone M, Femia EA, Cattaneo M. Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. Platelets 2018; 29 (7): 644-649.
• Hayward CPM, Moffat KA, Brunet J, Carlino SA, Plumhoff E, Meijer P, Zehnder JL. Update on diagnostic testing for platelet function disorders: What is pratical and useful? Int J Lab Hematol 2019; 41 (Suppl 1): 26-32
• Gresele P, Orsini S, Noris P, Falcinelli E, Alleci MC, Bury L, Borhany M, Santoro C, Glembotsky AC, Cid AR, Tosetto A, De Candia E, Fontan P, Guglielmini G, Pecci A, BAT-VAL study investigators (57). Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. J Thromb Haemost 2020; 18 (3): 732:739.
• Rabbolini D, Connor D, Morel-Kopp MC, Donikian D, Kondo M, Chen W, Alessi MC, Stevenson W, Chen V, Joseph J, Brighton C, Ward C, Sydney Platelet Group. An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. Pathology 2020; 52 (2): 243-255.

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.

In today episode, our expert Charlotte Parent, Marketing product manager, will talk with us about the EQA. A valuable tool to ensure the quality of laboratory results.

As usual, don’t forget to send any question you may have to ask@stago.com, we will be glad to answer to it.

Literature sources:

• Ask Stago season 1 episode 3: eIQC and EQA: benefits and differences  https://www.podcastics.com/podcast/episode/3-eiqc-and-eqa-benefits-and-differences-35848/
• ISO 15189:2012, Medical laboratories — Requirements for quality and competence
• ISO 13528:2015 Statistical methods for use in proficiency testing by interlaboratory comparison

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.<